Capricor Therapeutics Inc (NASDAQ:CAPR) Sees Significant Increase in Short Interest

Capricor Therapeutics Inc (NASDAQ:CAPR) was the target of a large growth in short interest during the month of December. As of December 15th, there was short interest totalling 5,590,000 shares, a growth of 26.8% from the November 30th total of 4,410,000 shares. Based on an average daily volume of 3,570,000 shares, the short-interest ratio is currently 1.6 days.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on CAPR shares. Piper Sandler assumed coverage on Capricor Therapeutics in a research report on Monday, October 21st. They issued an “overweight” rating and a $35.00 price target for the company. Maxim Group raised their target price on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the stock a “buy” rating in a report on Wednesday, September 25th. HC Wainwright reiterated a “buy” rating and set a $77.00 price target on shares of Capricor Therapeutics in a report on Thursday, November 14th. Cantor Fitzgerald raised their price objective on shares of Capricor Therapeutics from $25.00 to $30.00 and gave the stock an “overweight” rating in a research note on Thursday, November 14th. Finally, Oppenheimer reaffirmed an “outperform” rating and set a $15.00 target price on shares of Capricor Therapeutics in a research note on Monday, September 23rd. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. According to MarketBeat, Capricor Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $34.50.

Capricor Therapeutics Price Performance

Capricor Therapeutics stock opened at $13.76 on Tuesday. The stock has a market cap of $625.67 million, a price-to-earnings ratio of -12.98 and a beta of 3.98. The firm has a 50-day moving average of $17.23 and a two-hundred day moving average of $10.70. Capricor Therapeutics has a 1 year low of $3.52 and a 1 year high of $23.40.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the company. Renaissance Technologies LLC lifted its holdings in shares of Capricor Therapeutics by 158.7% in the 2nd quarter. Renaissance Technologies LLC now owns 137,500 shares of the biotechnology company’s stock worth $656,000 after buying an additional 84,350 shares during the period. Marshall Wace LLP purchased a new stake in Capricor Therapeutics in the second quarter worth about $426,000. Point72 Asset Management L.P. bought a new position in Capricor Therapeutics during the 3rd quarter worth about $3,806,000. State Street Corp increased its position in Capricor Therapeutics by 27.8% during the 3rd quarter. State Street Corp now owns 512,313 shares of the biotechnology company’s stock valued at $7,792,000 after purchasing an additional 111,291 shares during the period. Finally, The Manufacturers Life Insurance Company purchased a new position in Capricor Therapeutics during the 3rd quarter valued at about $161,000. 21.68% of the stock is currently owned by hedge funds and other institutional investors.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.